Neuronal hyperactivity - A key defect in Alzheimer's disease?

BioEssays

Volumn 37, Issue 6, 2015, Pages 624-632

  Busche, Marc Aurel ^a   Konnerth, Arthur ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; Amyloid ; Biomedicine; Brain imaging; Mouse models; Neuronal dysfunction; Neuronal hyperactivity

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTICONVULSIVE AGENT; CALCIUM; DIAZEPAM; ETIRACETAM; MONOCLONAL ANTIBODY; PROTEINASE INHIBITOR; SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BOLD SIGNAL; BRAIN CORTEX; BRAIN DYSFUNCTION; CELL POPULATION; CLINICAL TRIAL (TOPIC); CONNECTOME; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HYPERACTIVITY; IN VIVO STUDY; INHIBITION (PSYCHOLOGY); MULTIPHOTON MICROSCOPY; NERVE CELL; NERVE CELL NETWORK; NERVE CELL STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; STRIATE CORTEX; TRANSGENIC MOUSE; ANIMAL; FEEDBACK SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; FEEDBACK, PHYSIOLOGICAL; HIPPOCAMPUS; HUMANS; NEURONS; PLAQUE, AMYLOID; SYNAPTIC TRANSMISSION;

EID: 84929513259     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201500004     Document Type: Review

References (112)

1. Förstl H, Kurz A. 1999. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249: 288-90.
2. Holtzman DM, Morris JC, Goate AM. 2011. Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr1.
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 7: 280-92.
4. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, et al. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-28.
5. Golde TE, Schneider LS, Koo EH. 2011. Anti-Aß therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69: 203-13.
6. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid ß-peptide. Nat Rev Mol Cell Biol 8: 101-12.
7. Bertram L, Lill CM, Tanzi RE. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68: 270-81.
8. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl J Med 367: 795-804.
9. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, et al. 2013. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207-16.
10. Oddo S, Caccamo S, Kitazawa S, Tseng BP, et al. 2003. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-70.
11. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1: a006189.
12. Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aß 42 fibrils. Science 293: 1491-5.
13. Lewis J, Dickson DW, Lin WL, Chisholm L, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-91.
14. Oddo S, Billings L, Kesslak JP, Cribbs DH, et al. 2004. Aß immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-32.
15. Jin M, Shepardson N, Yang T, Chen G, et al. 2011. Soluble amyloid ß-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad of Sci USA 108: 5819-24.
16. Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron 6: 487-98.
17. Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-5.
18. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-6.
19. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, et al. 1996. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aß1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-13.
20. Duff K, Eckman C, Zehr C, Yu X, et al. 1996. Increased amyloid-ß42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-3.
21. Citron M, Westaway D, Xia W, Carlson G, et al. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid ß-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72.
22. Steiner H, Capell A, Leimer U, Haass C. 1999. Genes and mechanisms involved in ß-amyloid generation and Alzheimer's disease. Eur Arch Psych Clin Neurosci 249: 266-70.
23. Verghese PB, Castellano JM, Holtzman DM. 2011. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10: 241-52.
24. Huang Y. 2010. Aß-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 16: 287-94.
25. Huang Y, Mahley RW. 2014. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis 72(Pt A): 3-12.
26. Karran E, Mercken M, De Strooper B. 2011. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712.
27. Jonsson T, Atwal JK, Steinberg S, Snaedal J, et al. 2012. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-9.
28. Hsia AY, Masliah E, McConlogue L, Yu GQ, et al. 1999. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 3228-33.
29. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298: 789-91.
30. Kamenetz F, Tomita T, Hsieh H, Seabrook G, et al. 2003. APP processing and synaptic function. Neuron 37: 925-37.
31. Snyder EM, Nong Y, Almeida CG, Paul S, et al. 2005. Regulation of NMDA receptor trafficking by amyloid-ß. Nat Neurosci 8: 1051-8.
32. Hsieh H, Boehm J, Sato C, Iwatsubo T, et al. 2006. AMPAR removal underlies Aß-induced synaptic depression and dendritic spine loss. Neuron 52: 831-43.
33. Johnson KA, Fox NC, Sperling RA, Klunk WE. 2012. Brain imaging in Alzheimer disease. Cold Spring Harbor Perspect Med 2: a006213.
34. Palop JJ, Mucke L. 2009. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66: 435-40.
35. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, et al. 2007. Reducing endogenous tau ameliorates amyloid ß-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-4.
36. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, et al. 2008. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321: 1686-9.
37. Roberson ED, Halabisky B, Yoo JW, Yao J, et al. 2011. Amyloid-ß/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-11.
38. Busche MA, Chen X, Henning HA, Reichwald J, et al. 2012. Critical role of soluble amyloid-ß for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad of Sci USA 109: 8740-5.
39. Sanchez PE, Zhu L, Verret L, Vossel KA, et al. 2012. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad of Sci USA 109: E2895-903.
40. Bakker A, Krauss GL, Albert MS, Speck CL, et al. 2012. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74: 467-74.
41. Stosiek C, Garaschuk O, Holthoff K, Konnerth A. 2003. In vivo two-photon calcium imaging of neuronal networks. Proc Natl Acad of Sci USA 100: 7319-24.
42. Helmchen F, Denk W. 2005. Deep tissue two-photon microscopy. Nat Methods 2: 932-40.
43. Grienberger C, Konnerth A. 2012. Imaging calcium in neurons. Neuron 73: 862-85.
44. Tian L, Hires SA, Looger LL. 2012. Imaging neuronal activity with genetically encoded calcium indicators. Cold Spring Harb Protoc 2012: 647-56.
45. Smetters D, Majewska A, Yuste R. 1999. Detecting action potentials in neuronal populations with calcium imaging. Methods 18: 215-21.
46. Scanziani M, Hausser M. 2009. Electrophysiology in the age of light. Nature 461: 930-9.
47. Games D, Adams D, Alessandrini R, Barbour R, et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F ß-amyloid precursor protein. Nature 373: 523-7.
48. Hsiao K, Chapman P, Nilsen S, Eckman C, et al. 1996. Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
49. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, et al. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad of Sci USA 94: 13287-92.
50. Holcomb L, Gordon MN, McGowan E, Yu X, et al. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100.
51. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, et al. 1998. Neuron loss in APP transgenic mice. Nature 395: 755-6.
52. Spires TL, Hyman BT. 2004. Neuronal structure is altered by amyloid plaques. Rev Neurosci 15: 267-78.
53. Grutzendler J, Helmin K, Tsai J, Gan WB. 2007. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease. Ann N Y Acad Sci 1097: 30-9.
54. Siskova Z, Justus D, Kaneko H, Friedrichs D, et al. 2014. Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease. Neuron 84: 1023-33.
55. Chen G, Chen KS, Knox J, Inglis J, et al. 2000. A learning deficit related to age and ß-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975-9.
56. Lesne S, Koh MT, Kotilinek L, Kayed R, et al. 2006. A specific amyloid-ß protein assembly in the brain impairs memory. Nature 440: 352-7.
57. Grienberger C, Rochefort NL, Adelsberger H, Henning HA, et al. 2012. Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nature Commun 3: 774.
58. Rudinskiy N, Hawkes JM, Betensky RA, Eguchi M, et al. 2012. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nat Neurosci 15: 1422-9.
59. Lalonde R, Dumont M, Staufenbiel M, Strazielle C. 2005. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res 157: 91-8.
60. Palop JJ, Chin J, Roberson ED, Wang J, et al. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711.
61. Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, et al. 2008. Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol 1: 157-68.
62. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, et al. 2009. Amyloid ß-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29: 3453-62.
63. Heneka MT, Kummer MP, Stutz A, Delekate A, et al. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-8.
64. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. 2009. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323: 1211-5.
65. West MJ, Coleman PD, Flood DG, Troncoso JC. 1994. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344: 769-72.
66. Abramowski D, Wiederhold KH, Furrer U, Jaton AL, et al. 2008. Dynamics of Aß turnover and deposition in different ß-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 327: 411-24.
67. 2+ influx induced by ß-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J Neurobiol 26: 325-38.
68. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, et al. 2008. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11: 1311-8.
69. Abramov E, Dolev I, Fogel H, Ciccotosto GD, et al. 2009. Amyloid-ß as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12: 1567-76.
70. Fogel H, Frere S, Segev O, Bharill S, et al. 2014. APP homodimers transduce an amyloid-ß-mediated increase in release probability at excitatory synapses. Cell Rep 7: 1560-76.
71. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, et al. 2009. Oligomeric amyloid ß associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad of Sci USA 106: 4012-7.
72. Kerr JN, Greenberg D, Helmchen F. 2005. Imaging input and output of neocortical networks in vivo. Proc Natl Acad of Sci USA 102: 14063-8.
73. Rochefort NL, Garaschuk O, Milos RI, Narushima M, et al. 2009. Sparsification of neuronal activity in the visual cortex at eye-opening. Proc Natl Acad of Sci USA 106: 15049-54.
74. Laughlin SB, Sejnowski TJ. 2003. Communication in neuronal networks. Science 301: 1870-4.
75. Jia H, Rochefort NL, Chen X, Konnerth A. 2010. Dendritic organization of sensory input to cortical neurons in vivo. Nature 464: 1307-12.
76. O'Keefe J, Dostrovsky J. 1971. The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res 34: 171-5.
77. O'Keefe J, Speakman A. 1987. Single unit activity in the rat hippocampus during a spatial memory task. Exp Brain Res 68: 1-27.
78. Wilson IA, Ikonen S, Gallagher M, Eichenbaum H, et al. 2005. Age-associated alterations of hippocampal place cells are subregion specific. J Neurosci 25: 6877-86.
79. Wilson IA, Gallagher M, Eichenbaum H, Tanila H. 2006. Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci 29: 662-70.
80. Patrylo PR, Tyagi I, Willingham AL, Lee S, et al. 2007. Dentate filter function is altered in a proepileptic fashion during aging. Epilepsia 48: 1964-78.
81. Koh MT, Haberman RP, Foti S, McCown TJ, et al. 2010. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology 35: 1016-25.
82. Cacucci F, Yi M, Wills TJ, Chapman P, et al. 2008. Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad of Sci USA 105: 7863-8.
83. Vossel KA, Beagle AJ, Rabinovici GD, Shu H, et al. 2013. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70: 1158-66.
84. Harris KD, Thiele A. 2011. Cortical state and attention. Nat Rev Neurosci 12: 509-23.
85. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, et al. 2001. A default mode of brain function. Proc Natl Acad of Sci USA 98: 676-82.
86. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, et al. 2009. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63: 178-88.
87. O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN, et al. 2010. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 74: 1969-76.
88. Dickerson BC, Salat DH, Greve DN, Chua EF, et al. 2005. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65: 404-11.
89. Miller SL, Fenstermacher E, Bates J, Blacker D, et al. 2008. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psych 79: 630-5.
90. Quiroz YT, Budson AE, Celone K, Ruiz A, et al. 2010. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol 68: 865-75.
91. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, et al. 2000. Patterns of brain activation in people at risk for Alzheimer's disease. New Engl J Med 343: 450-6.
92. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, et al. 2009. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad of Sci USA 106: 7209-14.
93. Putcha D, Brickhouse M, O'Keefe K, Sullivan C, et al. 2011. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J Neurosci 31: 17680-8.
94. Elman JA, Oh H, Madison CM, Baker SL, et al. 2014. Neural compensation in older people with brain amyloid-ß deposition. Nat Neurosci 17: 1316-8.
95. Palop JJ, Mucke L. 2010. Amyloid-ß-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13: 812-8.
96. Truccolo W, Donoghue JA, Hochberg LR, Eskandar EN, et al. 2011. Single-neuron dynamics in human focal epilepsy. Nat Neurosci 14: 635-41.
97. Arieli A, Sterkin A, Grinvald A, Aertsen A. 1996. Dynamics of ongoing activity: explanation of the large variability in evoked cortical responses. Science 273: 1868-71.
98. Gilbert CD, Sigman M. 2007. Brain states: top-down influences in sensory processing. Neuron 54: 677-96.
99. Li S, Hong S, Shepardson NE, Walsh DM, et al. 2009. Soluble oligomers of amyloid ß protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62: 788-801.
100. Verret L, Mann EO, Hang GB, Barth AM, et al. 2012. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149: 708-21.
101. Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, et al. 2010. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci 30: 13707-17.
102. Leung L, Andrews-Zwilling Y, Yoon SY, BJain S, et al. 2012. Apolipoprotein E4 causes age- and sex-dependent impairments of hilar GABAergic interneurons and learning and memory deficits in mice. PloS ONE 7: e53569.
103. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, et al. 2005. Synaptic activity regulates interstitial fluid amyloid-ß levels in vivo. Neuron 48: 913-22.
104. Bero AW, Yan P, Roh JH, Cirrito JR, et al. 2011. Neuronal activity regulates the regional vulnerability to amyloid-ß deposition. Nat Neurosci 14: 750-6.
105. Sakata S, Harris KD. 2009. Laminar structure of spontaneous and sensory-evoked population activity in auditory cortex. Neuron 64: 404-18.
106. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, et al. 2005. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25: 7709-17.
107. Yan P, Bero AW, Cirrito JR, Xiao Q, et al. 2009. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 29: 10706-14.
108. Salloway S, Sperling R, Fox NC, Blennow K, et al. 2014. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New Engl J Med 370: 322-33.
109. Doody RS, Thomas RG, Farlow M, Iwatsubo T, et al. 2014. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New Engl J Med 370: 311-21.
110. Born HA, Kim JY, Savjani RR, Das P, et al. 2014. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci 34: 3826-40.
111. Ittner LM, Ke YD, Delerue F, Bi M, et al. 2010. Dendritic function of tau mediates amyloid-ß toxicity in Alzheimer's disease mouse models. Cell 142: 387-97.
112. Morris M, Maeda S, Vossel K, Mucke L. 2011. The many faces of tau. Neuron 70: 410-26.